MetLife Investment Management LLC boosted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) by 37.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,712 shares of the company’s stock after purchasing an additional 7,251 shares during the quarter. MetLife […]
Moody Aldrich Partners LLC acquired a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 38,064 shares of the company’s stock, valued at approximately $1,406,000. Moody Aldrich Partners LLC owned about 0.06% of Amylyx Pharmaceuticals at […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) major shareholder Morningside Venture Investment sold 29,048 shares of the firm’s stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $30.45, for a total transaction of $884,511.60. Following the completion of the sale, the insider now owns 6,997,302 […]
The IPO market has been slow this year as investors’ risk appetite for new issues hit a record low. As of last month, there were just 161 initial publ
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) had its price target raised by equities researchers at Citigroup from $32.00 to $33.00 in a report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 145.17% from the stock’s current price. Amylyx […]